Clinical Trials Logo

FLT3-ITD Mutation clinical trials

View clinical trials related to FLT3-ITD Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT03642236 Enrolling by invitation - Clinical trials for Acute Myeloid Leukemia

Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Start date: August 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Clinical efficacy of FLT3 inhibitors combining with chemotherapy is usually transient and followed by emergence of drug-resistance in FLT3-ITD mutant AML. BTK is reported to be a therapeutic target in this subtype leukemia. Our previous study showed inhibition of BTK onvercome drug-resistance to FLT3 inhibitors/chemotherapy in refractory/relapsed FLT3 mutant AML. In this prospective randomized controlled study, the efficacy and safety of combination of BTK inhibitor with chemotherapy with/without FLT3 inhibitor in refractory/relapsed FLT3 mutant AML are evaluated.

NCT ID: NCT03622541 Completed - AML Clinical Trials

Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD

Start date: November 15, 2010
Phase: Phase 2
Study type: Interventional

Patients with refractory or relapsed acute myeloid leukemia (AML) after two courses of standard chemotherapy regimens have very limited options. Further chemotherapy is associated with significant toxicity and is generally ineffective. About 10-30% patients with AML carry a gain-of-function mutation of a gene known as Flt3 in the leukemic cells, conferring them with abnormal cellular proliferation. Sorafenib is a multi-kinase inhibitor which was licensed in Hong Kong for the treatment of advanced hepatocellular and renal cell carcinoma. The drug has also been shown to be effective against Flt3 and AML but it has not been licensed for use in this condition.

NCT ID: NCT03620318 Available - FLT3-ITD Mutation Clinical Trials

Individual Patient Compassionate Use of Crenolanib

Start date: n/a
Phase:
Study type: Expanded Access

Compassionate use of crenolanib for patients with serious life-threatening illness that have exhausted all available therapies used to treat the disease, with no other viable therapy options, who is not eligible for clinical trials. This program is designed to evaluate the requests on a patient by patient basis. Patients must have documented evidence of a point mutation in position 842 in platelet derived growth factor receptor alpha (PDGFRA-D842V) or amplification of PDGFRA or internal tandem duplication within the FMS-like tyrosine kinase 3 (FLT3-ITD) or point mutations within the tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD)

NCT ID: NCT03547258 Recruiting - AML Clinical Trials

Italian Non-Interventional Study of FLT3 Mutated AML Patients

FLAM
Start date: July 18, 2018
Phase:
Study type: Observational

This is an observational study involving a retrospective and prospective collection of clinical and molecular data regarding patients with AML with FLT3+ mutations

NCT ID: NCT03170895 Completed - AML Clinical Trials

Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD

Start date: July 1, 2017
Phase: Phase 2
Study type: Interventional

The study aims to test if combination of sorafenib and omacetaxine mepesuccinate (OM, also known as homoharringtonine) results in durable composite complete remission (CRc) in patients with newly diagnosed or relapsed/refractory (R/R) acute myeloid leukemia (AML) carrying FLT3-ITD (Fms-Like Tyrosine Kinase 3 - Internal Tandem Duplication).

NCT ID: NCT03135054 Active, not recruiting - AML Clinical Trials

Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD

Start date: October 1, 2017
Phase: Phase 2
Study type: Interventional

The study aims to test if combination of quizartinib (AC220) and omacetaxine mepesuccinate (OM, also known as homoharringtonine) results in durable composite complete remission (CRc) in patients with newly diagnosed or relapsed/refractory (R/R) acute myeloid leukemia (AML) carrying FLT3-ITD (Fms-Like Tyrosine Kinase 3 - Internal Tandem Duplication).

NCT ID: NCT02156297 Recruiting - Clinical trials for Acute Myeloid Leukemia

Sorafenib to Treat FLT3-ITD AML

Start date: June 2014
Phase:
Study type: Observational

It is a prospective, non-interventional, open-label study, in order to observe the safety and response in FLT3-ITD mutation positive AML patients who receiving sorafenib as induction, consolidation, salvage, maintenance or alleviative treatment. The duration of the study from June 2014 through May 2019, with the recruitment duration from June 2014 to May 2017. The inclusion criteria is: 1. Definitely diagnosed as AML 2. FLT3-ITD mutation has been confirmed 3. Accepting the prescription of sorafenib